2026-09-21 · Brand
Overseas, a Medical Device Brand Isn't Built by Advertising
I spent several years in the medical device industry, working on tenders and product analysis — infusion pumps, syringe pumps, TCI pumps, and home ventilators (CPAP) among them, with markets including Africa. When I started I thought the business was fought over specs and price. It isn't. Those two are the entry ticket.
Whoever writes the tender spec tends to win it
Anyone who has bid knows this: the technical parameters in a tender document are not a neutral description. Whoever can get their own product spec written into the document has won half the contest before evaluation starts. Half a decimal place of accuracy, one extra alarm function, one constraint on power supply — any of them can eliminate half the field.
This usually gets filed under "relationships," which isn't quite right. A better description: the spec is the power to translate a product's strengths into the buyer's language. The company that has been in the market longest, sat through the most clinical feedback rounds, and talked to hospital equipment departments the most times is the one most likely to see the spec written in the shape it already fits. That's what a brand actually is at the technical level — not awareness, but the right to define.
The second order isn't won on specs. It's won on service radius
What decides repeat purchase is a different question: when a unit fails, how long until somebody with spare parts is standing in the doorway of the machine room.
An infusion pump down in a provincial capital hospital — repaired in 48 hours or in two weeks — are two entirely different things to the doctor using it. He isn't afraid of equipment failing; equipment always fails. He's afraid of it failing with nobody accountable, a patient coming to harm, and the blame landing on him. In markets where the spare-parts chain is long and local engineers are scarce, that fear is decisive.
So when I judge whether a brand has genuinely established itself in a country, I don't look at awareness surveys. I look at three things: which city the parts inventory sits in, how many clinical training sessions were run last year, and average days to repair. Those three numbers rarely appear in a slide deck, and they're more accurate than any brand story.
Price wins the first order; service wins the second
The standard playbook for Chinese manufacturers going abroad is to cut price first. Price does win the first order, especially in public projects with tight budgets and short procurement cycles. The problem is what comes after: often there is no second order. Nobody tends the account, the machines sit in a corridor gathering dust, and at the next tender the buyer tries someone else.
On paper these two kinds of spending are completely different. Discounting is a marketing cost — spent, and gone. A local parts inventory, trained engineers and a repair process that actually works are assets, and they pay you back at the next tender. The only difference is timing: the first hits this period's expense line, the second takes two or three years to show up — and most overseas ventures are measured on the current year.
What "brand" means here is selling the risk down
Back to the word brand. In a clinical setting, what a brand does is shrink the risk the other party carries: the doctor's risk is that something goes wrong and nobody covers him; the buyer's risk is that the decision gets questioned later; the distributor's risk is holding stock he can't move. Advertising solves "they've heard of you." Service and training solve "they dare to use you." In markets with weak regulation, tight budgets and high doctor turnover, the second half of that sentence is worth considerably more than the first.
The same logic holds in other industries — only the shape of the risk changes. If you want to know whether a brand has really established itself in a market, don't ask users whether they recognise the name. Ask: when something goes wrong, who shows up?